Related Experiment Video
Updated: Feb 2, 2026
Cerenkov Luminescence Imaging CLI for Cancer Therapy Monitoring
Published on: November 13, 2012
Antiangiogenic Gene Therapy in Cancer
L Zhang1, Q R Chen1, A J Mixson1
1Department of Pathology, University of Maryland at Baltimore, MD 21201.
Abstract:
One of the most recent and exciting approaches in cancer gene therapy is the ability to target the developing blood supply of the tumor. An appealing feature of antiangiogenic gene therapy is that the tumor vasculature is a readily accessible target, particularly when the carrier and its gene are administered systemically. This is in contrast to several other gene therapy approaches in which the tumor vasculature represents a major obstacle to achieving high levels of transfection of the tumor cells. Several gene-based viral or non-viral therapies that target tumor angiogenesis have shown efficacy in pre-clinical models. Genes that encode antiangiogenic polypeptides such as angiostatin and endostatin have significantly inhibited tumor growth, inducing a microscopic dormant state. The products of these genes are thought to act extracellularly to inhibit angiogenesis. An alternative approach that investigators have used successfully in tumor-bearing mice is to target angiogenic growth factors or their receptors that are essential for tumor growth. Levels of angiogenic factors such as vascular endothelial growth factor (VEGF) have been reduced by either antisense methods or the use of genes encoding truncated angiogenic decoy receptors. Despite these promising findings of tumor reduction with antiangiogenic gene therapy, advances in the viral and/or non-viral delivery systems are essential for this therapy to have clinical utility. In this review, we will discuss the mechanisms of angiogenesis/antiangiogenesis, and the current status and future directions of antiangiogenic gene therapy.
Insights
Antiangiogenic gene therapy targets tumor blood supply, inhibiting growth by blocking new blood vessel formation. Advances in delivery systems are crucial for clinical application of this promising cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- Tumor angiogenesis, the development of new blood vessels supplying tumors, is a critical target for cancer treatment.
- Antiangiogenic gene therapy offers a novel approach by targeting tumor vasculature, which is often accessible via systemic administration.
- Unlike other gene therapies where tumor vasculature can be a barrier, it serves as a target for antiangiogenic strategies.
Purpose of the Study:
- To review the mechanisms of angiogenesis and antiangiogenesis in the context of cancer.
- To discuss the current status and future directions of antiangiogenic gene therapy.
- To highlight the potential of targeting tumor vasculature for cancer treatment.
Main Methods:
- Review of pre-clinical studies utilizing gene-based viral and non-viral therapies.
- Analysis of gene-encoded antiangiogenic polypeptides (e.g., angiostatin, endostatin).
- Investigation of strategies targeting angiogenic growth factors (e.g., VEGF) or their receptors.
Main Results:
- Gene therapies encoding antiangiogenic proteins like angiostatin and endostatin have shown significant tumor growth inhibition in pre-clinical models.
- Targeting angiogenic factors or receptors, such as vascular endothelial growth factor (VEGF), using antisense methods or decoy receptors has proven effective.
- These approaches can induce a dormant state in tumors by inhibiting extracellular angiogenesis.
Conclusions:
- Antiangiogenic gene therapy demonstrates significant promise in pre-clinical cancer models by inhibiting tumor growth.
- Further advancements in viral and non-viral delivery systems are essential for the clinical translation of antiangiogenic gene therapy.
- Targeting tumor angiogenesis represents a viable and exciting frontier in cancer gene therapy research.
Related Concept Videos
00:59Gene Therapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...